RecruitingNCT04202341

Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

Long-Term, Observational, Global Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies (C5ITs)

Sponsor

Alexion Pharmaceuticals, Inc.

Enrollment

500 participants

Start Date

Dec 2, 2019

Study Type

OBSERVATIONAL

Conditions

Generalized Myasthenia Gravis

Summary

Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a registry study — not a treatment trial — for people with generalized myasthenia gravis (gMG) who are being treated with Alexion's complement inhibitor therapies (C5 inhibitors), which include Soliris (eculizumab) and Ultomiris (ravulizumab). Myasthenia gravis is a chronic autoimmune condition that causes muscle weakness, including in the face, arms, legs, and breathing muscles. The registry is collecting long-term data on patients treated with these medications to better understand how well they work in real-world settings, their safety over time, and how patients' lives are affected. This is important because clinical trials don't always reflect the diversity of patients seen in everyday medical practice. You may be eligible if: - You have been diagnosed with generalized myasthenia gravis - You are currently being treated with a C5 inhibitor (Soliris or Ultomiris), or were previously treated and have since stopped - You are 18 or older and can provide informed consent - You have historical myasthenia gravis data (such as MG-ADL and MGFA scores) available You may NOT be eligible if: - You are currently enrolled in an Alexion-sponsored interventional clinical trial for gMG treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(51)

Clinical Trial Site

Birmingham, Alabama, United States

Clinical Trial Site

Scottsdale, Arizona, United States

Clinical Trial Site

Fresno, California, United States

Clinical Trial Site

Orange, California, United States

Clinical Trial Site

Rancho Mirage, California, United States

Clinical Trial Site

Sylmar, California, United States

Clinical Trial Site

Colorado Springs, Colorado, United States

Clinical Trial Site

Fort Collins, Colorado, United States

Clinical Trial Site

New Haven, Connecticut, United States

Clinical Trial Site

Washington D.C., District of Columbia, United States

Clinical Trial Site

Clearwater, Florida, United States

Clincal Trial Site

Gainesville, Florida, United States

Clinical Trial Site

Jacksonville, Florida, United States

Clinical Trial Site

Tampa, Florida, United States

Clinical Trial Site

Augusta, Georgia, United States

Clinical Trial Site

Iowa City, Iowa, United States

Clinical Trial Site

Lexington, Kentucky, United States

Clinical Trial Site

Boston, Massachusetts, United States

Clinical Trial Site

Lansing, Michigan, United States

Clinical Trial Site

Columbia, Missouri, United States

Clinical Trial Site

New Hyde Park, New York, United States

Clinical Trial Site

Chapel Hill, North Carolina, United States

Clinical Trial Site

Charlotte, North Carolina, United States

Clinical Trial Site

Durham, North Carolina, United States

Clinical Trial Site

Dayton, Ohio, United States

Clinical Trial Site

Philadelphia, Pennsylvania, United States

Clinical Trial Site

Chattanooga, Tennessee, United States

Clinical Trial Site

Knoxville, Tennessee, United States

Clinical Trial Site

Dallas, Texas, United States

Clinical Trial Site

Houston, Texas, United States

Clinical Trial Site

Burlington, Vermont, United States

Clinical Trial Site

Milwaukee, Wisconsin, United States

Clinical Trial Site

Vienna, Austria

Clinical Trial Site

Brampton, Ontario, Canada

Clinical Trial Site

London, Ontario, Canada

Clinical Trial Site

Montreal, Quebec, Canada

Clinical Trial Site

Chengdu, Sichuan, China

Clinical Trial Site

Beijing, China

Clinical Trial Site

Changchun, China

Clinical Trial Site

Chengdu, China

Clinical Trial Site

Guangzhou, China

Clinical Trial Site

Jinan, China

Clinical Trial Site

Nanchang, China

Clinical Trial Site

Qingdao, China

Clinical Trial Site

Shijiazhuang, China

Clinical Trial Site

Hanover, Hannover, Germany

Clinical Trial Site

Milan, Italy

Clinical Trial Site

Naples, Italy

Clinical Trial Site

Abhā, Saudi Arabia

Clinical Trial Site

Jeddah, Saudi Arabia

Clinical Trial Site

Riyadh, Saudi Arabia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04202341

Related Trials

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

NCT06744920100 locations

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

NCT06517758113 locations

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

NCT069875391 location

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

NCT0619388917 locations

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

NCT060559599 locations